纽约 - 专注于开发iNKT细胞疗法用于治疗癌症和其他疾病的生物制药公司MiNK Therapeutics, Inc. (NASDAQ: INKT)宣布已重新符合纳斯达克的上市要求。该公司目前股价为$9.49，年初至今回报率达36%，尽管市值相对较小，为$37.64million，但展现出强劲的韧性。根据 InvestingPro ...

MiNK Therapeutics (INKT) has received formal notice from Nasdaq confirming that the company has regained compliance with both the minimum bid ...

Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory ...

DeAndre Hopkins said he would honor his late father at Super Bowl 59 by wearing the mink coat he left the Chiefs receiver.

A policy to control invasive minks in Leicestershire and Rutland in a bid to protect water vole populations has been approved ...

Mink Ventures Corporation (TSXV:MINK) (“ Mink ” or the " Company ") today announced that it has completed all share issuances and incurred all expenditures required to earn a 100% interest in the ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mink Ventures Corporation (TSXV:MINK) (“Mink” or the "Company") today announced that it has completed all share issuances and incurred all ...